GBA Presents: THE GREEN MARKET

stonedinvestor said:
BDSI--

If you are going to have an analyst day it's good to have something to talk about. This interests me--

Investor Dayon October 14, 2021

RALEIGH, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has completed the acquisition of U.S. and Canadian rights to ELYXYB™ (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited.

ELYXYB is the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. BDSI intends to launch ELYXYB in the first quarter of 2022. Additionally, BDSI plans to conduct an ELYXYB pediatric study, which will have the potential to address the significant unmet needs of pediatric and adolescent patients suffering from migraine attacks.

Migraine is a debilitating condition for almost 40 million people in the U.S. Many acute migraine sufferers are searching for treatments that provide relief quickly and conveniently.

“The availability of ELYXYB represents a significant therapeutic development for the acute treatment of migraine,” stated Richard Lipton, MD, Edwin S. Lowe Chair in Neurology at Albert Einstein College of Medicine, Director of the Montefiore Headache Center, and one of the clinical investigators for the ELYXYB studies. “With rapid onset of action delivered in a unique, ready-to-use oral solution, ELYXYB provides a convenient, quick relief treatment option to help patients return to functioning in their everyday lives.”

ELYXYB is an oral solution of celecoxib, formulated using a self-micro emulsifying drug delivery system that improves solubility and bioavailability of the drug leading to better absorption1. This allows for the administration of a lower dose of drug to achieve therapeutic effect relative to a conventional oral solid dosage form. For adult patients who suffer from the debilitating and disruptive effects of migraine, there continues to be a need for reliable and efficacious treatment options. ELYXYB’s unit-dose oral solution makes it convenient for patients to take it immediately upon emergence of acute migraine attacks.

“ELYXYB’s pivotal studies showed that the percentage of patients achieving Most Bothersome Symptom (MBS) freedom at two hours post-dose was significantly greater for those patients receiving ELYXYB versus those receiving placebo. Study 2 demonstrated that the percentage of patients reaching headache pain freedom two hours post-dose was significantly greater for those receiving ELYXYB versus those receiving placebo. The data also showed meaningful speed of onset with Tmaxachieved in approximately 60 minutes,” said Thomas Smith, MD, Chief Medical Officer at BDSI, and a former thought leader in the migraine space. “BDSI looks forward to expanding our impact in Migraine and to deepening our commitment to our patients-first philosophy.”

<< What is significantly better? We will find out today. 52%? language a little wishy washy >>

“The acquisition of ELYXYB represents a critical step to building our presence in Neurology which is an excellent strategic adjacency to our pain franchise,” said Jeff Bailey, CEO of BDSI.

“We are confident that ELYXYB will contribute to BDSI’s revenue growth and profitability over time, with patent protection until 2036. Our extensive commercial expertise, robust corporate infrastructure, and strong financial position will allow us to successfully commercialize ELYXYB and continue to pursue additional value-enhancing business development opportunities,” Bailey indicated.

BDSI will host an Investor Day on October 14, 2021, to discuss ELYXYB in further detail.
More...
 
Well well well. Look at What I have Done--- created the ole dipsy due'

OCT 14 analyst day BDSI into <---------

OCT 18 date for Oculur at FDA! <-------

watch and learn everyone or better yet play along! A master is about to paint....

 
One Trade into another: The Dipsy Doo Made famous 1990's

Not this:

dipsy doodle
noun, often attributive

dip·sy doo·dle | \ ¦dipsē¦düdᵊl \

variants: or less commonly dipsy doo \ -dü \

plural -s

Definition of dipsy doodle


1 slang : a bewildering plunge and lag by turns the dipsy doodle price of rice shows how unsound the country's economy is

2 slang : artfully deceptive or shady manipulation not theorists, not the advocates of any alien philosophies or political dipsy doo— Joseph W. Martin

3 : a very slow curve on a pitched ball in baseball







 
stonedinvestor said:
Ocugen (OCGN) has been one of the more polarizing story stocks of 2021. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via a reverse merger with floundering biotech shell Histogenics. Ocugen had been in operation since 2013 with the goal of "develop[ing] innovative therapies to treat rare and underserved eye diseases". The company had raised $19 millionin debt and equity through the life of the company and has de minimis existing revenues today.

As the below chart shows, markets had little interest in this penny stock between the closing of the reverse merger in late 2019 through late 2020.



Another new COVID-19 stock!
That suddenly changed on December 22, 2020 when Ocugen announcedthat they had a new agreement with India's Bharat Biotech to commercialize Bharat's COVAXIN within the United States. Since then, the stock has surged more than 2,000%, from less than $0.30 to more than $7.00 today, and currently sports a market cap of more than $1.5 billion.

This seems like a VAN short
More...
Short? He's long with smart guys like me making bank on this gem. Don't doubt the smoking fish. But yes, it could collapse at any moment. High risk trade.
 
You must log in or register to reply here.
Back
Top